Anti-TRAM1 Antibody Picoband®

Overview

Anti-TRAM1 Antibody Picoband® is an antibody reagent for detection of TRAM1 (olfactomedin 4). Researchers commonly use anti-TRAM1 antibodies to measure relative expression and localization across biological samples, with assay selection guided by the listed applications (WB, IHC, Flow, ELISA).

Boster Bio Anti-TRAM1 Antibody Picoband® catalog # A04106. Tested in Flow Cytometry, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Target: TRAM1 — Chromodomain-helicase-DNA-binding protein 2 (olfactomedin 4). Alternative names: Olfactomedin-4; OLM4; Antiapoptotic protein GW112; G-CSF-stimulated clone 1 protein; hGC-1; hOLfD; OLFM4; GW112; UNQ362; PRO698
• Antibody format: Polyclonal; Rabbit IgG
• Species context: Host: Rabbit, Reactivity: Human,Mouse,Rat
• Purification: Immunogen affinity purified.
• Immunogen: A synthetic peptide corresponding to a sequence at the C-terminus of human TRAM1, which shares 89.5% amino acid (aa) sequence identity with mouse and rat TRAM1.
• Molecular weight context: observed 55-60 kDa, calculated 211344 MW (reported)
• Provided application(s): WB, IHC, Flow, ELISA

These attributes help contextualize how the antibody is commonly selected (host/clonality/isotype/label) and how signals are interpreted across sample types and assay formats.

Biological background

Function: May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin.

Cellular localization: Extracellular space. Mitochondrion.

Tissue details: Expressed during myeloid lineage development. Much higher expression in bone marrow neutrophils than in peripheral blood neutrophils (at protein level). Strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. Overexpressed in some pancreatic cancer tissues.

Background: TRAM1(Translocation-Associating Membrane Protein 1), By crosslinking and reconstitution of canine proteoliposomes, followed by microsequencing and PCR screening of canine kidney and HeLa cell cDNA libraries, Gorlich et al.(1992) isolated cDNAs encoding TRAM(translocating chain-associating membrane protein). The International Radiation Hybrid Mapping Consortium mapped the TRAM gene to chromosome 8. Sequence analysis predicted that human TRAM is a 374-amino acid, 8-pass transmembrane protein that shares 95% amino acid identity with the canine protein. Functional analysis indicated that TRAM influences glycosylation and is stimulatory or required for the translocation of secretory proteins.

Cross reactivity: No cross-reactivity with other proteins.

Research relevance and current trends

• Quantitative and spatial profiling: expression patterns are increasingly studied across cell states using multiplex imaging and omics-informed validation.
• Isoforms and post-translational modifications: researchers often evaluate how isoform composition and PTMs can shift apparent molecular weight or localization.
• Context-aware interpretation: comparative studies commonly include perturbations (stimulation, inhibition, genetic models) to relate target changes to pathway behavior.

Common research applications

• Western blot (WB): compare relative target abundance and apparent size shifts (e.g., isoforms/PTMs) across conditions.
• Immunohistochemistry (IHC): assess distribution across tissue compartments and compare staining patterns between groups.
• Flow cytometry: quantify target-positive populations and compare shifts after stimulation or differentiation.

Across these uses, researchers typically interpret changes in signal as relative differences between matched sample groups, considering sample preparation and biological context.

Notes for experimental interpretation

• Apparent molecular weight can vary due to isoforms, proteolysis, glycosylation, phosphorylation, and sample preparation differences.
• Species reactivity and epitope conservation can influence observed signal patterns, especially in cross-species studies.
• Control concepts: include appropriate negative controls (e.g., isotype controls where relevant) and, when feasible, genetic or orthogonal controls (KO/KD, peptide competition, or independent assays) to support interpretation.

For antibody reagents, monoclonal antibodies are often chosen for epitope consistency across lots, while polyclonals may recognize multiple epitopes and can show different background characteristics depending on context.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.